Journal of Nephrological Science最新文献

The Role of CT-Based Radiomics in Precise Imaging of Renal Cancer 基于ct的放射组学在肾癌精确成像中的作用

Journal of Nephrological Science Pub Date : 2021-07-06 DOI: 10.29245/2767-5149/2021/2.1111

M. Ligero, K. Bernatowicz, R. Perez-Lopez

引用次数: 0

Alterations of cAMP/cGMP Signaling Pathways in Lupus Nephritis 狼疮性肾炎中cAMP/cGMP信号通路的改变

Journal of Nephrological Science Pub Date : 2021-06-08 DOI: 10.29245/2767-5149/2021/2.1112

Issaka Yougbare

{"title":"Alterations of cAMP/cGMP Signaling Pathways in Lupus Nephritis","authors":"Issaka Yougbare","doi":"10.29245/2767-5149/2021/2.1112","DOIUrl":"https://doi.org/10.29245/2767-5149/2021/2.1112","url":null,"abstract":"Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad spectrum of clinical manifestations, but its pathogenesis remains fairly understood. Cyclic nucleotide signaling pathways in immune cells and kidney are emerging as cellular mechanisms governing SLE disease progression. Upregulations of cGMP/cAMP metabolism lead to lupus nephritis and abnormal kidney remodeling/hypertrophy. PDE4 family remains the major cAMP hydrolyzing enzyme as PDE1 is responsible for cGMP breakdown in kidney. SLE disease progression to lupus nephritis is correlated with increase PDE1 and PDE4 activities resulting in lower cyclic nucleotide levels in kidney. Administration of Nimodipine, a PDE1 inhibitor prevents the lymphoproliferative phenotype and exert anti-proliferative effects on mesangial cells while PDE4 inhibitor NCS 613 prevents inflammatory cytokines release, immune complex deposition, and nephritis in MRL/lpr lupus prone mice. In this review, we highlight recent findings of alterations of cyclic nucleotide signaling pathways in lupus nephritis. Given the role of cAMP/cGMP signaling in kidney function, dual inhibition of PDE1 and PDE4 may represent a promising therapeutic approach to tackle lupus nephritis.","PeriodicalId":174935,"journal":{"name":"Journal of Nephrological Science","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132237794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact? 氨磷汀在接受顺铂治疗的患者中是一种肾保护剂——神话、谜团还是事实?

Journal of Nephrological Science Pub Date : 2021-02-15 DOI: 10.29245/2767-5149/2021/1.1109

Sin Sil Ha, Kazi Rubaina, Chung-Shien Lee, V. John, N. Seetharamu

引用次数: 4

Commentary: Cannabinoids in Urology. Which Benign Conditions Might they be Appropriate to Treat: A Systematic Review 评论:大麻素在泌尿外科。哪些良性疾病可能适合治疗:系统回顾

Journal of Nephrological Science Pub Date : 2021-01-15 DOI: 10.29245/2767-5149/2021/1.1110

C. Taylor, B. Birch

引用次数: 0

Lysophosphatidic Acid Prevents Ischemia Reperfusion Injury but does not Prevent Tubular Dysfunction 溶血磷脂酸可预防缺血再灌注损伤，但不能预防小管功能障碍

Journal of Nephrological Science Pub Date : 2020-12-15 DOI: 10.29245/2767-5149/2020/2.1108

S. R. Gonsalez, A. L. Cortês, M. Romanelli, Paula Mattos-Silva, Andrew C. Curnow, Minolfa C. Prieto, M. Einicker‐Lamas, L. Lara

{"title":"Lysophosphatidic Acid Prevents Ischemia Reperfusion Injury but does not Prevent Tubular Dysfunction","authors":"S. R. Gonsalez, A. L. Cortês, M. Romanelli, Paula Mattos-Silva, Andrew C. Curnow, Minolfa C. Prieto, M. Einicker‐Lamas, L. Lara","doi":"10.29245/2767-5149/2020/2.1108","DOIUrl":"https://doi.org/10.29245/2767-5149/2020/2.1108","url":null,"abstract":"Lysophosphatidic acid (LPA) protects the kidneys from tissue ischemic reperfusion injury (IRI), but its impact on renal function is primarily limited to glomerular function. We estimated the status of renal function by a complete glomerular and tubular functional analysis to test the hypothesis that LPA treatment during ischemia-reperfusion (I/R) protects renal function by attenuating IRI. Male Wistar rats were subjected to bilateral kidney I/R. Along with ischemia, LPA was administered. LPA increased levels of plasma LPA, downregulated LPA2R, prevented interstitial fibronectin and TGF-β1 accumulation, and prevented a decrease in glomerular filtration rate (GFR). I/R increased urine volume and proteinuria and decreased fractional Na+ excretion (FENa) and urine osmolality. These effects were not prevented by LPA. The reduction in FENa was attributed to disruption in tubular Na+ transport and downregulation of protein kinase C (PKC) activity. LPA treatment maintained (Na++K+)ATPase activity to the control level, due to a sustained sensitivity to PLC/PKC pathway. Na+-ATPase activity was insensitivity to LPA treatment. This ineffectiveness was associated with downregulation of LPA2R, resulting in low FENa. Altogether, LPA treatment maintained normal kidney structure and prevented the reduction of glomerular function. However, even in the setting of preserved GFR, impaired tubular function may present a high risk for silent progression of kidney disease.","PeriodicalId":174935,"journal":{"name":"Journal of Nephrological Science","volume":"121 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130493425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Multiple Myeloma: An Uncommon Presentation of a Common Neurological Problem 多发性骨髓瘤:一种常见神经系统疾病的罕见表现

Journal of Nephrological Science Pub Date : 2020-07-20 DOI: 10.29245/2767-5149/2020/1.1105

Mansoor Ali

引用次数: 0

Use of Polyacrylamide Hydrogel for Vesicoureteral Reflux Treatment, a Review 聚丙烯酰胺水凝胶在膀胱输尿管反流治疗中的应用综述

Journal of Nephrological Science Pub Date : 2019-09-11 DOI: 10.29245/2767-5149/2019/1.1102

S. Bolduc

{"title":"Use of Polyacrylamide Hydrogel for Vesicoureteral Reflux Treatment, a Review","authors":"S. Bolduc","doi":"10.29245/2767-5149/2019/1.1102","DOIUrl":"https://doi.org/10.29245/2767-5149/2019/1.1102","url":null,"abstract":"Purpose of the review: Vesicoureteral reflux (VUR) is a common pathology encountered in pediatric urology. If left untreated, this condition can lead to infectious complications, hypertension and loss of renal function by scars. There is a trend for minimally invasive procedures to minimise treatment-related complications. Endoscopic subureteral injection of bulking agent in the treatment of VUR is an example of minimally invasive options. Several bulking agents have been studied and the perfect agent has not yet been discovered. Polyacrylamide hydrogel is a relatively new agent used to treat VUR and its use will be reviewed. Recent findings: Three modern studies from a Canadian group have evaluated the use of polyacrylamide hydrogel for endoscopic injection to treat VUR. The first study reported a cure rate of 81.2% without major complication. In the second study, injection of polyacrylamide hydrogel was compared to dextranomer hyaluronic acid and no significant difference was observed, with overall success rate of 73.1% and 77.5% respectively. The third trial evaluated the long-term efficacy and safety of polyacrylamide hydrogel with a 36-month follow-up. Overall success at 3 months was 70.7% and no patient had de novo hydronephrosis or calcification of the agent at 36 months. Conclusion: Polyacrylamide hydrogel seems to be a safe and effective alternative bulking agent in the treatment of VUR. The contribution from other centers to validate those data would be valuable.","PeriodicalId":174935,"journal":{"name":"Journal of Nephrological Science","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133380661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Thalassemia and Nephrolithiasis 地中海贫血和肾结石

Journal of Nephrological Science Pub Date : 2019-09-11 DOI: 10.29245/2767-5149/2019/1.1101

B. Joob

引用次数: 1